Accountability for the Diversity Plan to Improve Enrollment of Underrepresented Populations in Clinical Trials
Date/Time
November 30, 2022
Panelists
Del Smith
Co-founder and CEO, Acclinate
Ingrid Oakley-Girvan
SVP of Research and Strategy, Medable
Ricki Fairley
CEO, Touch, The Black Breast Cancer Alliance
Racquel Racadio
Director, Global Representation in Clinical Research, Amgen
Ed Ramos
Director, Digital Clinical Trials at Scripps Research and Principal Science Officer at CareEvolution, Inc
MIchel Reid
Sr. Director and Head, Global Demographics & Diversity, GSK
Sam Eells
Co-Founder at Lightship
Moderator
Jonah Comstock
Editor in Chief, Pharmaphorum
Discussion Topic
Everyone’s talking about the lack of diversity, equity, and inclusion in clinical trials. The FDA issued draft guidance to provide recommendations to help clinical trial sponsors develop a Race and Ethnicity Diversity Plan. Some House Democrats are also pushing for Congressional legislation to secure more representation in clinical trials. We all recognize the need to do something about it, but who’s going to lead the efforts? Who’s going to be accountable for increasing diversity in clinical trials?
Leaders from across the clinical trials ecosystem give an update on the Diversity, Equity, and Inclusion in Digitized Clinical Trials project, and an in-depth discussion on what different stakeholders can do to ensure digital technologies are used to increase diversity, equity, and inclusion in clinical trials.